Anthrax lethal factor endopeptidase

Chapter
Part of the Springer Handbook of Enzymes book series (HDBKENZYMES, volume S6)

Keywords

Protective Antigen Bacillus Anthracis Lethal Factor Lethal Toxin Anthrax Toxin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Vitale, G; Bernardi, L; Napolitani, G; Mock, M; Montecucco, C.: Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem. J., 352, 739–745 (2000)PubMedCrossRefGoogle Scholar
  2. [2]
    Duesbery, N.S., Webb, C.P.; Leppla, S.H.; Gordon, V.M.; Klimpel, K.R.; Copeland, T.D.; Ahn, N.G.; Oskarsson, M.K.; Fukasawa, K.; Paull, K.D.; Vande Woude, G.F.: Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science, 280, 734–737 (1998)PubMedCrossRefGoogle Scholar
  3. [3]
    Pannifer, A.D.; Wong, T.Y.; Schwarzenbacher, R.; Renatus, M.; Petosa, C.; Bienkowska, J.; Lacy, D.B.; Collier, R.J.; Park, S.; Leppla, S.H.; Hanna, P.; Liddington, R.C.: Crystal structure of the anthrax lethal factor. Nature, 414, 229–233 (2001)PubMedCrossRefGoogle Scholar
  4. [4]
    Tonello, F.; Ascenzi, P.; Montecucco, C.: The metalloproteolytic activity of the anthrax lethal factor is substrate-inhibited. J. Biol. Chem., 278, 40075–40078 (2003)PubMedCrossRefGoogle Scholar
  5. [5]
    Pellizzari, R.; Guidi-Rontani, C.; Vitale, G.; Mock, M.; Montecucco, C.: Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNγ-induced release of NO and TNFα. FEBS Lett., 462, 199–204 (1999)PubMedCrossRefGoogle Scholar
  6. [6]
    Rossetto, O.; de Bernard, M.; Pellizzari, R.; Vitale, G.; Caccin, P.; Schiavo, G.; Montecucco, C.: Bacterial toxins with intracellular protease activity. Clin. Chim. Acta, 291, 189–199 (2000)PubMedCrossRefGoogle Scholar
  7. [7]
    Glomski, I.J.; Fritz, J.H.; Keppler, S.J.; Balloy, V.; Chignard, M.; Mock, M.; Goossens, P.L.: Murine splenocytes produce inflammatory cytokines in MyD88-dependent response to Bacillus anthracis spores. cell. Microbiol., 9, 502–513 (2007)PubMedCrossRefGoogle Scholar
  8. [8]
    Gubbins, M.J.; Berry, J.D.; Corbett, C.R.; Mogridge, J.; Yuan, X.Y.; Schmidt, L.; Nicolas, B.; Kabani, A.; Tsang, R.S.: Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen. FEMS Immunol. Med. Microbiol., 47, 436–443 (2006)PubMedCrossRefGoogle Scholar
  9. [9]
    Bergman, N.H.; Passalacqua, K.D.; Gaspard, R.; Shetron-Rama, L.M.; Quackenbush, J.; Hanna, P.C.: Murine macrophage transcriptional responses to Bacillus anthracis infection and intoxication. Infect. Immun., 73, 1069–1080 (2005)PubMedCrossRefGoogle Scholar
  10. [10]
    Comer, J.E.; Galindo, C.L.; Chopra, A.K.; Peterson, J.W.: GeneChip analyses of global transcriptional responses of murine macrophages to the lethal toxin of Bacillus anthracis. Infect. Immun., 73, 1879–1885 (2005)PubMedCrossRefGoogle Scholar
  11. [11]
    Koya, V.; Moayeri, M.; Leppla, S.H.; Daniell, H.: Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge. Infect. Immun., 73, 8266–8274 (2005)PubMedCrossRefGoogle Scholar
  12. [12]
    Xu, L.; Frucht, D.M.: Bacillus anthracis: A multi-faceted role for anthrax lethal toxin in thwarting host immune defenses. Int. J. Biochem. Cell Biol., 39, 20–24 (2007)PubMedCrossRefGoogle Scholar
  13. [13]
    Baillie, L.W.J.: Past, imminent and future human medical countermeasures for anthrax. J. Appl. Microbiol., 101, 594–606 (2006)PubMedCrossRefGoogle Scholar
  14. [14]
    Cui, X.; Li, Y.; Li, X.; Haley, M.; Moayeri, M.; Fitz, Y.; Leppla, S.H.; Eichacker, P.Q.: Sublethal doses of Bacillus anthracis lethal toxin inhibit inflammation with lipopolysaccharide and Escherichia coli challenge but have opposite effects on survival. J. Infect. Dis., 193, 829–840 (2006)PubMedCrossRefGoogle Scholar
  15. [15]
    Gujraty, K.; Sadacharan, S.; Frost, M.; Poon, V.; Kane, R.S.; Mogridge, J.: Functional characterization of peptide-based anthrax toxin inhibitors. Mol. Pharmacol., 2, 367–372 (2005)CrossRefGoogle Scholar
  16. [16]
    Boyden, E.D.; Dietrich, W.F.: Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat. Genet., 38, 240–244 (2006)PubMedCrossRefGoogle Scholar
  17. [17]
    Mendelson, I.; Gat, O.; Aloni-Grinstein, R.; Altboum, Z.; Inbar, I.; Kronman, C.; Bar-Haim, E.; Cohen, S.; Velan, B.; Shafferman, A.: Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components. Vaccine, 23, 5688–5697 (2005)PubMedCrossRefGoogle Scholar
  18. [18]
    Sloat, B.R.; Cui, Z.: Nasal immunozation with a dual antigen anthrax vacine induced strong mucosal and systemic immune responses against toxins and bacilli. Vaccine, 24, 6405–6413 (2006)PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Personalised recommendations